LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
TXMD
TherapeuticsMD, Inc.
There isn't enough reported data to score TXMD yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
TXMD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Strong | |
| Strong |
TXMD's cash flow and balance sheet are currently strong, but its profitability is weak. There isn't enough data to rate its revenue.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
TXMD PE Valuation
TXMD has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
TXMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect TXMD's revenue to grow, with its earnings and profitability holding steady.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over TXMD on earnings quality, reporting a profit while its opponent remains loss making.
TXMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.02 | +$0.03 |
| Q1 2026 | $0.02 | +$0.21 |
| Q4 2025 | -$0.05 | +$0.14 |
| Q3 2025 | $0.01 | +$0.26 |
| Q2 2025 | -$0.05 | +$0.47 |
| Q1 2025 | -$0.19 | +$0.48 |
| Q4 2024 | -$0.19 | +$0.79 |
| Q3 2024 | -$0.25 | -103% |
TXMD lost $0.02 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over TXMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over TXMD on profitability, with a higher operating margin.
TXMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $869K | -8.7% |
| Q1 2026 | $724K | +84% |
| Q4 2023 | $502K | -56% |
| Q2 2023 | $437K | -98% |
| Q1 2023 | $416K | -98% |
| Q4 2022 | $1.2M | -94% |
| Q3 2022 | $20.9M | -18% |
| Q2 2022 | $28.6M | +24% |
TXMD's revenue is growing: $869,000 last quarter, down 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -94% | -21 points |
| Q1 2026 | -100% | +122 points |
| Q4 2025 | -174% | N/A |
| Q3 2025 | -110% | N/A |
| Q2 2025 | -73% | N/A |
| Q1 2025 | -222% | N/A |
| Q4 2023 | -321% | -6138 points |
| Q2 2023 | -566% | -500 points |
TXMD's operating margin was −94% last quarter, down 21 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
TXMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $779K | +104% |
| Q1 2026 | $944K | +35% |
| Q4 2025 | $375K | +2106% |
| Q3 2025 | $999K | +$1.1M |
| Q2 2025 | $381K | -74% |
| Q1 2025 | $699K | +$928K |
| Q4 2024 | $17K | +$5M |
| Q3 2024 | -$71K | +$2.4M |
TXMD has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over TXMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
TXMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +74K shares |
| 1 year | +0.8% | +91K shares |
| 3 years | +24% | +2.3M shares |
| 5 years | +114% | +6.2M shares |
| Available history | +141% | +6.8M shares |
TXMD has 12M diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2023 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
TXMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -0.0x | Net Cash |
| Q2 2023 | -0.3x | Net Cash |
| Q1 2023 | -0.7x | Net Cash |
| Q4 2022 | -16.0x | Net Cash |
TXMD has more cash than debt.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
TXMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.0 | Neutral |
| Stochastic | 18.2 | Oversold |
TXMD's weekly RSI is 41 (neutral) and its Stochastic is 18 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
TXMD PE vs Healthcare Sector
| Metric | TXMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
TXMD has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over TXMD on trend strength, trading above more of its moving averages.
TXMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.90 | 4.2% below |
| 20 week MA | $2.02 | 9.9% below |
| 50 week MA | $2.06 | 12% below |
| 100 week MA | $1.62 | 12% above |
| 200 week MA | $2.20 | 17% below |
TXMD's trend is mixed: it's above one of its five weekly moving averages, and 17% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over TXMD on returns for 2026, with the stronger performance.
TXMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $120.5 | $59.5 | -51% |
| 2021 | $59.5 | $20.5 | -66% |
| 2022 | $20.5 | $5.62 | -73% |
| 2023 | $5.62 | $2.25 | -60% |
| 2024 | $2.25 | $1.09 | -52% |
| 2025 | $1.09 | $1.74 | +60% |
| 2026 YTD | $1.74 | $1.82 | +4.6% |
TXMD has finished lower in five of the last six years. It's up 4.6% so far in 2026.